The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
Published in Leukemia
Imatinib is not a potent anti-SARS-CoV-2 drug
Published in Leukemia
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acut...
...Published in Leukemia
Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic l...
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
...Published in Leukemia
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precur...
...Published in Leukemia
Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia.
...Published in Leukemia
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
...Published in Leukemia
Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with ...
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia.
Published in Leukemia
Chronic myeloid leukemia (CML) is characterized by expression of the tyrosine kinase oncogene, Bcr-abl. Tyrosine kinase inhibitors (TKI) induce prolonged remission in CML, and therapy discontinuation is an accepted approach to patients with reduction in Bcr-abl transcripts of four logs or greater. Half such individuals sustain a therapy free remiss...
SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
...Published in Leukemia
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells.
...Published in Leukemia
The use of immunotherapy to treat patients with myelodysplastic syndromes (MDS) shows promise but is limited by our incomplete understanding of the immunologic milieu. In solid tumors, CD141Hi conventional dendritic cells (CD141Hi cDCs) are necessary for antitumor immunosurveillance and the response to immunotherapy. Here, we found that CD141Hi cDC...
